Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary-Elizabeth M Percival

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Cancer|July 11, 2019
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemiaMary-Elizabeth M Percival, Elihu H Estey
Leukemia & Lymphoma|June 23, 2020
Truth or consequences: under-reporting of post-accrual changes in clinical trial designMary-Elizabeth M Percival, Elihu H Estey
Leukemia & Lymphoma|March 11, 2021
Are phase III trials still important for FDA drug approval?Mary-Elizabeth M Percival, Elihu H Estey
Leukemia Research|December 16, 2014
Chemotherapy dose in obese AML patients: to cap or not to cap?Mary-Elizabeth M Percival, Bruno C Medeiros
Hematology. American Society of Hematology. Education Program|December 5, 2025
Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approachesSuravi Raychaudhuri, Ryan D Cassaday, Mary-Elizabeth M Percival
Oncology (Williston Park, N.Y.)|May 27, 2014
Bulky mediastinal classical Hodgkin lymphoma in young womenMary-Elizabeth M Percival, Richard T Hoppe, Ranjana H Advani
Cancer|March 6, 2015
Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysisMary-Elizabeth M Percival, Li Tao, Bruno C Medeiros, et al.
Leukemia|August 5, 2022
Evaluating concordance in assessment of ECOG performance status in acute myeloid leukemia patientsNicole Mostofi, Carole Shaw, Roland B Walter, et al.
Blood Neoplasia|August 12, 2025
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapySuravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2020
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid NeoplasmRaffaele Palmieri, Megan Othus, Anna B Halpern, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Cancer|July 11, 2019
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemiaMary-Elizabeth M Percival, Elihu H Estey
Leukemia & Lymphoma|June 23, 2020
Truth or consequences: under-reporting of post-accrual changes in clinical trial designMary-Elizabeth M Percival, Elihu H Estey
Leukemia & Lymphoma|March 11, 2021
Are phase III trials still important for FDA drug approval?Mary-Elizabeth M Percival, Elihu H Estey
Leukemia Research|December 16, 2014
Chemotherapy dose in obese AML patients: to cap or not to cap?Mary-Elizabeth M Percival, Bruno C Medeiros
Hematology. American Society of Hematology. Education Program|December 5, 2025
Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approachesSuravi Raychaudhuri, Ryan D Cassaday, Mary-Elizabeth M Percival
Oncology (Williston Park, N.Y.)|May 27, 2014
Bulky mediastinal classical Hodgkin lymphoma in young womenMary-Elizabeth M Percival, Richard T Hoppe, Ranjana H Advani
Cancer|March 6, 2015
Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysisMary-Elizabeth M Percival, Li Tao, Bruno C Medeiros, et al.
Leukemia|August 5, 2022
Evaluating concordance in assessment of ECOG performance status in acute myeloid leukemia patientsNicole Mostofi, Carole Shaw, Roland B Walter, et al.
Blood Neoplasia|August 12, 2025
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia receiving intensive chemotherapySuravi Raychaudhuri, Megan Othus, Mary-Elizabeth M Percival, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2020
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid NeoplasmRaffaele Palmieri, Megan Othus, Anna B Halpern, et al.
Pageof 6